Page Menu

Squamous Cell Carcinoma Clinical Trial

By participating in a squamous cell carcinoma clinical trial, an individual can be among the first patients to receive a promising new treatment that is not yet available in other settings. The advantages of these important studies are twofold: patients can begin benefiting from breakthrough treatments as soon as possible, and researchers can assess the effectiveness of these new treatments as compared to the current standard of care. If the new treatment proves to be more effective, or equally effective with fewer side effects, it may become the new standard of care for all patients with squamous cell carcinoma.

As the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, Moffitt Cancer Center is leading the way in cancer research. Through extensive scientific studies and robust clinical trials, we are learning more each day about the causes, prevention and treatment of all forms of skin cancer. By participating in a squamous cell carcinoma clinical trial at Moffitt, patients can benefit from our very latest findings, such as encouraging new forms of:

  • Photodynamic therapy
  • Topical chemotherapy medications
  • Drugs that target specific cell proteins that have been linked to squamous cell carcinoma

Clinical trial participants at Moffitt are closely monitored by a multispecialty team of experts who specialize in treating skin cancer and collaborate to develop highly individualized treatment plans. In this way, we ensure that each patient benefits from multiple expert opinions, receives the most appropriate treatments and dosages and has the support necessary to manage any side effects. Our patients also benefit from the convenience of having access to all of our treatments and supportive services in a single location without referrals.

If you are interested in participating in a squamous cell carcinoma clinical trial, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online.

 

calledFromCancerPage=True - substr=
testProtocol=

Open Clinical Trials:

Showing of 50

CLINICAL TRIAL 19748

Phase II Randomized Trial of Radiotherapy with Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients with Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN Trial)

Disease Site: Head & Neck, Squamous Cell Carcinoma (SCC), Lip, Oral Cavity and Pharynx, Other Skin

View Trial Details

CLINICAL TRIAL 20144

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Disease Site: Head & Neck, Larynx, Lip, Oral Cavity and Pharynx, Squamous Cell Carcinoma (SCC)

View Trial Details

CLINICAL TRIAL 20162

Phase 1 Trial of Intralesional Immunotherapy with IFx-Hu2.0 Vaccine in Patients with Advanced Merkel Cell Carcinoma or Cutaneous Squamous Cell Carcinoma

Disease Site: Melanoma, skin, Merkel cell carcinoma (neuroendocrine skin cancer), Other Skin, Skin, Squamous Cell Carcinoma (SCC)

View Trial Details

CLINICAL TRIAL 20562

A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma

Disease Site: Other Skin, Skin, Squamous Cell Carcinoma (SCC)

View Trial Details

CLINICAL TRIAL 20731

Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Disease Site: Other Skin, Squamous Cell Carcinoma (SCC)

View Trial Details

CLINICAL TRIAL 21116

Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

Disease Site: Larynx, Lip, Oral Cavity and Pharynx, Head & Neck, Squamous Cell Carcinoma (SCC)

View Trial Details

CLINICAL TRIAL 20256

CemiplimAb Survivorship Epidemiology (CASE) Study

Disease Site: Squamous Cell Carcinoma (SCC), Other Skin

View Trial Details